research Phase 2, double-blind, randomized, placebo-controlled study of the safety and efficacy of elagolix in women with polycystic ovary syndrome
Elagolix did not effectively treat polycystic ovary syndrome.
Search
for
Sort by
Research
30 / 1000+ results
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
research Skin manifestations of hyperandrogenism: an update
Targeting androgen receptors in the skin is the most effective treatment for hyperandrogenism-related skin issues.
research Real-world pharmacovigilance insights into drug-induced risk of alopecia
64 drugs can cause hair loss, needing better monitoring and updated labels.
research Pharmacodynamic Evaluation: Endocrinology
The conclusion is that endocrinology significantly impacts medicine with various common medications used for treatment.
research DEVELOPMENT OF THE EMULGE LFOR THE ANDROGENIC ALOPECIA TREATMENT
The emulgel with specific ingredients was effective for treating hair loss.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism
The treatment temporarily improved symptoms of hyperandrogenism in adolescents.
research Quality control of the “Flavosterol” emulgel for androgenic alopecia prevention and treatment
The "Flavosterol" emulgel meets quality standards for treating hair loss.
research Table 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
research Rationale and design of the GLADE study: a randomized, multicenter, double-blind, placebo-controlled trial evaluating the safety and efficacy of gestrinone subdermal bioabsorbable pellet in endometriosis-related pelvic pain
Gestrinone pellets may help reduce pelvic pain in endometriosis safely.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Development and optimization of levofloxacin in-situ emulgel to manage ocular bacterial infections
Optimized emulgels with Levofloxacin effectively treat eye infections with prolonged drug release and safety.
research Ultra-low dose estradiol and dydrogesterone for the treatment of menopausal symptoms in a pooled, multi-ethnic population
research Development of emulgel technology with saw palmetto extracts and of japanese sophora tincture for androgenetic alopecia treatment
The emulgel with Saw Palmetto and Sophora Japonica shows promise for treating hair loss.
research Supplementary file 1_Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.docx
Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
research EMULGEL EMERGENT SYSTEMS: AT A GLANCE FOR TOPICAL DRUG DELIVERY
Emulgels are effective for delivering skin medications and cosmetics due to their easy application and controlled release.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Multifunctional ionic liquids-mediated topical delivery of minoxidil and EGCG for treating androgenic alopecia through promoting angiogenesis and scavenging ROS
New treatment using Minoxidil and EGCG with ionic liquids improves hair growth and quality for hair loss.
research Clobetasol/minoxidil
research Estrogens
research Latanoprost
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Latanoprost
A woman got a scalp condition from using latanoprost, but it improved after stopping the drug and starting other treatments.
research FORMULATION AND EVALUATION OF TOPICAL GEL CONTAINING HAIR GROWTH PROMOTERS FOR THE TREATMENT OF ANDROGENIC ALOPECIA
The emulgel formulation F6 released more Minoxidil than the gel formulation F1.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research LB1158 A novel more effective topical therapeutic approach for treatment of androgenetic alopecia: First in human trial results for topical ET-02
5% ET-02 is a more effective and safe treatment for hair loss than current options.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of Latanoprost for Eyelash Growth in Aesthetic Medicine
Latanoprost effectively and safely promotes eyelash growth.